"Most recently, CAP TODAY interviewed Dr. Shirley Li, assistant professor in the Department of Pathology, Ohio State University Wexner Medical Center, regarding new approaches to biomarkers for myocarditis diagnosis. At the AACC annual conference 2021, Dr. Li highlighted in her virtual presentation about the diagnostic value of miRNA in myocarditis. She cited the study from Dr. Pilar Martín, which was recently published in N Engl J Med. This study has evaluated and verified the application of miR-721 in the differential diagnosis between myocarditis and myocardial infarction.

“The inflammation and/or necrosis of cardiac tissues could happen at a very close time or in a certain time order, or mixed, happening at the same time,” Dr. Li explains. “We can see the similar trend of dynamic changes of troponin with the dynamic changes of inflammation biomarkers, but we are not able to confirm that troponin can differentiate myocarditis and myocardial infarction. The finding of novel microRNA”—the human homologue, designated as hsa-miR-Chr8:96—“can make it and fill the gap.” Meanwhile, “Troponin is a relatively more specific cardiac biomarker in the diagnosis of myocarditis, even in the course of COVID-19 vaccination,” said Dr. Li.

Please check more details in the interview on CAP TODAY.

最新一期的CAP 就miRNA 在心肌炎诊断的应用上采访了俄亥俄州立大学的李捷莉教授。李教授于去年AACC年会上主持了 有关心脏标志物的研讨会 并指出了miRNA 对心肌病诊断的潜在价值。 她援引了西班牙血管病专家Martin 博士于近期发表在新英格兰医学杂志的研究工作。该项研究评估并论证了miR-721可以用来鉴别诊断心肌炎和心肌梗塞。

李教授点评到“由于炎症和心肌坏死在发病时间和机制上有一定程度并存，临床上虽然Troponin和炎症标志物常呈现类似的动态变化，但是Troponin很难用来鉴别诊断心肌炎和心肌梗塞。而该miRNA的研究填补了这一空白。”与此同时，李教授认为因为较高的心肌特异性，Troponin对于心肌炎仍有诊断价值，包括近两年由新冠疫苗诱发的心肌炎。

详情请见CAP 网页

https://www.captodayonline.com/on-the-track-of-new-approaches-to-myocarditis/